TRML Insider Trading Activity and SEC Form 4 Filings
TRML insider trading summary
No open-market insider purchases or sales of Tourmaline Bio, Inc. (TRML) have been reported on SEC Form 4 in the past 12 months.
Latest TRML insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 21, 2024 | Sandeep Chidambar Kulkarni | CEO | Buy | $26K (1,779 @ $14.85) |
| Aug 16, 2024 | Sandeep Chidambar Kulkarni | CEO | Buy | $72K (5,221 @ $13.79) |
| Jan 29, 2024 | Mark McDade | Insider | Buy | $3.3M (100,000 @ $32.50) |
| Nov 17, 2023 | Parvinder Thiara | Director | Buy | $17K (1,000 @ $17.31) |
| Nov 17, 2023 | Sandeep Chidambar Kulkarni | CEO | Buy | $68K (4,000 @ $16.99) |
| Oct 27, 2023 | Caley Castelein | Director | Buy | $230K (15,800 @ $14.55) |
| Oct 26, 2023 | Sandeep Chidambar Kulkarni | CEO | Buy | $61K (5,000 @ $12.25) |
| Oct 25, 2023 | Parvinder Thiara | Director | Buy | $24K (2,000 @ $12.12) |
| Oct 25, 2023 | Caley Castelein | Director | Buy | $51K (4,200 @ $12.07) |
| Oct 24, 2023 | Aaron Kantoff | Director | Buy | $89K (7,500 @ $11.86) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.